Research AI

Scans

Tools

Watchlists

Home

Charts

Watchlist

Products

Shilpa Medicare Ltd

SHILPAMED

NSE

₹876.20-6.55%19 Oct 2026

Reports

Pharma API

Shilpa Medicare Ltd

SHILPAMED

NSE

₹876.20

-6.55%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Pharma API

Indices

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹16,932Cr

Close Price

₹865.70

Industry

Pharma API

Price To Earnings

55.14

Price To Sales

10.06

Revenue

₹1,683Cr

Rev Gr TTM

Revenue Growth TTM

27.95%

PAT Gr TTM

PAT Growth TTM

167.57%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	313	287	292	293	344	319	331	321	370	410	437	466
Growth YoY Revenue Growth YoY%	19.0	9.2	10.7	12.4	9.8	11.3	13.4	9.9	7.6	28.5	32.1	44.9
Expenses ExpensesCr	253	221	222	219	258	239	252	230	262	295	317	330
Operating Profit Operating ProfitCr	60	66	70	74	86	81	79	92	108	115	120	136
OPM OPM%	19.3	23.1	24.0	25.1	25.0	25.3	23.9	28.5	29.3	28.0	27.4	29.3
Other Income Other IncomeCr	0	1	8	6	5	2	-21	6	2	-13	45	9
Interest Expense Interest ExpenseCr	23	26	24	24	26	12	14	19	16	11	14	12
Depreciation DepreciationCr	28	27	27	27	28	29	29	29	30	30	31	35
PBT PBTCr	9	14	28	29	37	42	15	50	64	61	120	98
Tax TaxCr	8	9	3	15	19	10	1	3	20	16	13	-3
PAT PATCr	2	5	25	14	18	32	15	47	44	45	108	101
Growth YoY PAT Growth YoY%	108.5	171.0	404.0	1,091.5	1,042.7	576.2	-40.8	233.5	145.7	40.3	642.9	115.1
NPM NPM%	0.5	1.6	8.4	4.8	5.2	9.9	4.4	14.6	11.9	10.9	24.7	21.7
EPS EPS₹	0.1	0.3	1.4	0.7	0.9	1.6	0.4	2.4	2.8	2.3	5.5	5.2

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	313	287	292	293	344	319	331	321	370	410	437	466
Growth YoY Revenue Growth YoY%	19.0	9.2	10.7	12.4	9.8	11.3	13.4	9.9	7.6	28.5	32.1	44.9
Expenses ExpensesCr	253	221	222	219	258	239	252	230	262	295	317	330
Operating Profit Operating ProfitCr	60	66	70	74	86	81	79	92	108	115	120	136
OPM OPM%	19.3	23.1	24.0	25.1	25.0	25.3	23.9	28.5	29.3	28.0	27.4	29.3
Other Income Other IncomeCr	0	1	8	6	5	2	-21	6	2	-13	45	9
Interest Expense Interest ExpenseCr	23	26	24	24	26	12	14	19	16	11	14	12
Depreciation DepreciationCr	28	27	27	27	28	29	29	29	30	30	31	35
PBT PBTCr	9	14	28	29	37	42	15	50	64	61	120	98
Tax TaxCr	8	9	3	15	19	10	1	3	20	16	13	-3
PAT PATCr	2	5	25	14	18	32	15	47	44	45	108	101
Growth YoY PAT Growth YoY%	108.5	171.0	404.0	1,091.5	1,042.7	576.2	-40.8	233.5	145.7	40.3	642.9	115.1
NPM NPM%	0.5	1.6	8.4	4.8	5.2	9.9	4.4	14.6	11.9	10.9	24.7	21.7
EPS EPS₹	0.1	0.3	1.4	0.7	0.9	1.6	0.4	2.4	2.8	2.3	5.5	5.2

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	716	779	789	733	908	901	1,146	1,050	1,152	1,286	1,539	1,683
Growth Revenue Growth%	16.7	8.8	1.2	-7.0	23.8	-0.8	27.1	-8.3	9.7	11.7	19.6	27.9
Expenses ExpensesCr	556	608	627	578	688	719	942	948	907	967	1,104	1,204
Operating Profit Operating ProfitCr	160	171	162	156	220	182	204	102	245	319	435	479
OPM OPM%	22.3	22.0	20.6	21.3	24.2	20.2	17.8	9.7	21.2	24.8	28.3	28.5
Other Income Other IncomeCr	7	9	14	26	17	89	19	14	10	-9	39	43
Interest Expense Interest ExpenseCr	4	3	3	4	5	22	41	59	92	76	59	52
Depreciation DepreciationCr	23	31	37	42	44	54	80	96	108	113	120	126
PBT PBTCr	140	146	137	136	188	195	102	-38	54	122	295	344
Tax TaxCr	36	42	34	26	33	49	42	-7	22	44	52	46
PAT PATCr	105	104	103	110	155	146	61	-31	32	78	243	297
Growth PAT Growth%	44.2	-0.3	-1.5	6.5	41.1	-5.4	-58.6	-151.1	203.2	145.0	210.8	167.6
NPM NPM%	14.6	13.4	13.0	14.9	17.0	16.2	5.3	-3.0	2.8	6.1	15.8	17.7
EPS EPS₹	7.0	6.6	6.5	6.9	9.6	9.1	3.6	-1.9	1.8	2.0	12.4	15.7

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	716	779	789	733	908	901	1,146	1,050	1,152	1,286	1,539	1,683
Growth Revenue Growth%	16.7	8.8	1.2	-7.0	23.8	-0.8	27.1	-8.3	9.7	11.7	19.6	27.9
Expenses ExpensesCr	556	608	627	578	688	719	942	948	907	967	1,104	1,204
Operating Profit Operating ProfitCr	160	171	162	156	220	182	204	102	245	319	435	479
OPM OPM%	22.3	22.0	20.6	21.3	24.2	20.2	17.8	9.7	21.2	24.8	28.3	28.5
Other Income Other IncomeCr	7	9	14	26	17	89	19	14	10	-9	39	43
Interest Expense Interest ExpenseCr	4	3	3	4	5	22	41	59	92	76	59	52
Depreciation DepreciationCr	23	31	37	42	44	54	80	96	108	113	120	126
PBT PBTCr	140	146	137	136	188	195	102	-38	54	122	295	344
Tax TaxCr	36	42	34	26	33	49	42	-7	22	44	52	46
PAT PATCr	105	104	103	110	155	146	61	-31	32	78	243	297
Growth PAT Growth%	44.2	-0.3	-1.5	6.5	41.1	-5.4	-58.6	-151.1	203.2	145.0	210.8	167.6
NPM NPM%	14.6	13.4	13.0	14.9	17.0	16.2	5.3	-3.0	2.8	6.1	15.8	17.7
EPS EPS₹	7.0	6.6	6.5	6.9	9.6	9.1	3.6	-1.9	1.8	2.0	12.4	15.7

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	8	8	8	8	8	8	9	9	9	10	20
Reserves ReservesCr	632	979	1,077	1,189	1,321	1,471	1,814	1,775	1,800	2,353	2,572
Current Liabilities Current LiabilitiesCr	222	237	266	253	411	604	612	784	693	674	848
Non Current Liabilities Non Current LiabilitiesCr	67	251	153	167	257	561	453	345	600	273	266
Total Liabilities Total LiabilitiesCr	931	1,472	1,499	1,610	1,989	2,632	2,876	2,904	3,093	3,311	3,706
Current Assets Current AssetsCr	354	730	672	545	624	903	887	770	877	985	1,110
Non Current Assets Non Current AssetsCr	577	742	827	1,065	1,365	1,730	1,988	2,134	2,216	2,326	2,596
Total Assets Total AssetsCr	931	1,472	1,499	1,610	1,989	2,632	2,876	2,904	3,093	3,311	3,706

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	8	8	8	8	8	8	9	9	9	10	20
Reserves ReservesCr	632	979	1,077	1,189	1,321	1,471	1,814	1,775	1,800	2,353	2,572
Current Liabilities Current LiabilitiesCr	222	237	266	253	411	604	612	784	693	674	848
Non Current Liabilities Non Current LiabilitiesCr	67	251	153	167	257	561	453	345	600	273	266
Total Liabilities Total LiabilitiesCr	931	1,472	1,499	1,610	1,989	2,632	2,876	2,904	3,093	3,311	3,706
Current Assets Current AssetsCr	354	730	672	545	624	903	887	770	877	985	1,110
Non Current Assets Non Current AssetsCr	577	742	827	1,065	1,365	1,730	1,988	2,134	2,216	2,326	2,596
Total Assets Total AssetsCr	931	1,472	1,499	1,610	1,989	2,632	2,876	2,904	3,093	3,311	3,706

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	129	37	45	147	124	47	105	180	137	132	342
Investing Cash Flow Investing Cash FlowCr	-109	-262	-9	-196	-290	-404	-286	-233	-167	-199	-326
Financing Cash Flow Financing Cash FlowCr	-20	313	-61	10	176	436	83	46	47	63	14
Net Cash Flow Net Cash FlowCr	0	88	-25	-39	10	79	-98	-7	17	-4	30
Free Cash Flow Free Cash FlowCr	14	-79	-93	69	-220	-303	-226	-46	-48	-111	-28
CFO To PAT CFO To PAT%	122.9	35.9	43.7	134.0	80.5	32.1	173.5	-580.9	427.7	168.9	140.6
CFO To EBITDA CFO To EBITDA%	80.4	21.9	27.7	94.2	56.6	25.8	51.6	175.9	55.9	41.4	78.7

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	129	37	45	147	124	47	105	180	137	132	342
Investing Cash Flow Investing Cash FlowCr	-109	-262	-9	-196	-290	-404	-286	-233	-167	-199	-326
Financing Cash Flow Financing Cash FlowCr	-20	313	-61	10	176	436	83	46	47	63	14
Net Cash Flow Net Cash FlowCr	0	88	-25	-39	10	79	-98	-7	17	-4	30
Free Cash Flow Free Cash FlowCr	14	-79	-93	69	-220	-303	-226	-46	-48	-111	-28
CFO To PAT CFO To PAT%	122.9	35.9	43.7	134.0	80.5	32.1	173.5	-580.9	427.7	168.9	140.6
CFO To EBITDA CFO To EBITDA%	80.4	21.9	27.7	94.2	56.6	25.8	51.6	175.9	55.9	41.4	78.7

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	3,301	5,094	3,791	2,774	1,993	2,721	3,447	1,991	4,005	6,484	6,819	16,932
Price To Earnings Price To Earnings	32.1	47.3	36.0	24.7	12.8	18.4	56.8		125.7	82.8	28.0	55.1
Price To Sales Price To Sales	4.6	6.5	4.8	3.8	2.2	3.0	3.0	1.9	3.5	5.0	4.4	10.1
Price To Book Price To Book	5.1	5.2	3.5	2.3	1.5	1.8	1.9	1.1	2.2	2.7	2.6	6.5
EV To EBITDA EV To EBITDA	21.0	30.5	23.9	18.3	10.4	19.0	20.1	27.1	20.1	22.1	17.1	39.6
Profitability Ratios Profitability Ratios
GPM GPM%	42.9	45.6	47.5	55.1	60.7	59.6	56.5	49.3	55.7	59.0	60.8	60.8
OPM OPM%	22.3	22.0	20.6	21.3	24.2	20.2	17.8	9.7	21.2	24.8	28.3	28.5
NPM NPM%	14.6	13.4	13.0	14.9	17.0	16.2	5.3	-3.0	2.8	6.1	15.8	17.7
ROCE ROCE%	20.2	12.3	11.1	10.2	11.6	9.3	5.7	0.8	5.3	6.7	10.9	10.9
ROE ROE%	16.4	10.6	9.5	9.1	11.6	9.9	3.3	-1.7	1.8	3.3	9.4	9.4
ROA ROA%	11.3	7.1	6.9	6.8	7.8	5.5	2.1	-1.1	1.0	2.4	6.6	6.6
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	3,301	5,094	3,791	2,774	1,993	2,721	3,447	1,991	4,005	6,484	6,819	16,932
Price To Earnings Price To Earnings	32.1	47.3	36.0	24.7	12.8	18.4	56.8		125.7	82.8	28.0	55.1
Price To Sales Price To Sales	4.6	6.5	4.8	3.8	2.2	3.0	3.0	1.9	3.5	5.0	4.4	10.1
Price To Book Price To Book	5.1	5.2	3.5	2.3	1.5	1.8	1.9	1.1	2.2	2.7	2.6	6.5
EV To EBITDA EV To EBITDA	21.0	30.5	23.9	18.3	10.4	19.0	20.1	27.1	20.1	22.1	17.1	39.6
Profitability Ratios Profitability Ratios
GPM GPM%	42.9	45.6	47.5	55.1	60.7	59.6	56.5	49.3	55.7	59.0	60.8	60.8
OPM OPM%	22.3	22.0	20.6	21.3	24.2	20.2	17.8	9.7	21.2	24.8	28.3	28.5
NPM NPM%	14.6	13.4	13.0	14.9	17.0	16.2	5.3	-3.0	2.8	6.1	15.8	17.7
ROCE ROCE%	20.2	12.3	11.1	10.2	11.6	9.3	5.7	0.8	5.3	6.7	10.9	10.9
ROE ROE%	16.4	10.6	9.5	9.1	11.6	9.9	3.3	-1.7	1.8	3.3	9.4	9.4
ROA ROA%	11.3	7.1	6.9	6.8	7.8	5.5	2.1	-1.1	1.0	2.4	6.6	6.6
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	LAURUSLABS	COHANCE	SHILPAMED	ALIVUS	CONCORDBIO	SYMBIOTEC	AARTIPHARM
Market CapitalizationMkt CapCr	1,11,791	17,466	16,932	15,442	13,480	7,904	7,572
Close PriceClose₹	2,069.00	456.50	865.70	1,257.80	1,288.50	1,230.00	835.00
IndustryIndustry	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API
Price To EarningsPE	102.12	164.21	55.14	25.61	49.39	68.52	35.52
Price To SalesPS	15.38	8.16	10.06	5.96	12.16	9.09	3.85
RevenueRevenueCr	7,270	2,142	1,683	2,590	1,108	869	1,969
Revenue Growth TTMRev Gr TTM%	22.6%	-19.8%	27.9%	7.9%	-6.7%		1.2%
PAT Growth TTMPAT Gr TTM%	116.7%	-87.1%	167.6%	21.6%	-23.4%		-20.0%

	LAURUSLABS	COHANCE	SHILPAMED	ALIVUS	CONCORDBIO	SYMBIOTEC	AARTIPHARM
Market CapitalizationMkt CapCr	1,11,791	17,466	16,932	15,442	13,480	7,904	7,572
Close PriceClose₹	2,069.00	456.50	865.70	1,257.80	1,288.50	1,230.00	835.00
IndustryIndustry	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API	Pharma API
Price To EarningsPE	102.12	164.21	55.14	25.61	49.39	68.52	35.52
Price To SalesPS	15.38	8.16	10.06	5.96	12.16	9.09	3.85
RevenueRevenueCr	7,270	2,142	1,683	2,590	1,108	869	1,969
Revenue Growth TTMRev Gr TTM%	22.6%	-19.8%	27.9%	7.9%	-6.7%		1.2%
PAT Growth TTMPAT Gr TTM%	116.7%	-87.1%	167.6%	21.6%	-23.4%		-20.0%